Analysis of serious adverse events in a paediatric fast breathing pneumonia clinical trial in Malawi
Evangelyn Nkwopara, Robert Schmicker, Tisungane Mvalo, Melda Phiri, Ajib Phiri, Mari Couasnon, Eric D McCollum, Amy Sarah Ginsburg, Evangelyn Nkwopara, Robert Schmicker, Tisungane Mvalo, Melda Phiri, Ajib Phiri, Mari Couasnon, Eric D McCollum, Amy Sarah Ginsburg
Abstract
Introduction: Pneumonia is the leading infectious killer of children. We conducted a double-blind, randomised controlled non-inferiority trial comparing placebo to amoxicillin treatment for fast breathing pneumonia in HIV-negative children aged 2-59 months in Malawi. Occurrence of serious adverse events (SAEs) during the trial were examined to assess disease progression, co-morbidities, recurrence of pneumonia and side effects of amoxicillin.
Methods: Enrolled children with fast breathing for age and a history of cough <14 days or difficult breathing were randomised to either placebo or amoxicillin for 3 days, and followed for 14 days to track clinical characteristics and outcomes. Medical history, physical exam, laboratory results and any chest radiographs collected at screening, enrolment and during hospitalisation were evaluated. All SAE reports were reviewed for additional information regarding hospitalisation, course of treatment and outcome.
Results: In total, 102/1126 (9.0%) enrolled children with fast breathing pneumonia were reported to have a SAE. Seventy-five per cent (n=77) of SAEs were pneumonia-related (p<0.01). Children<2 years of age represented the greatest proportion (61/77, 79.2%) of those with a pneumonia-related SAE. In the amoxicillin group, there were 46 SAEs and 5 (10.9%) cases were identified as possibly related to study drug (4 gastroenteritis and 1 fever). There were no life-threatening pneumonia SAEs or deaths in either group, and by the time of exit from the study, all children recovered without sequelae.
Discussion: In this fast breathing pneumonia clinical trial, SAEs occurred infrequently in both the amoxicillin and placebo groups, and amoxicillin was well tolerated.
Trial registration number: NCT02760420. https://ichgcp.net/clinical-trials-registry/NCT02760420?term=ginsburg&rank=9.
Keywords: pneumonia.
Conflict of interest statement
Competing interests: None declared.
Figures
References
- Liu L, Oza S, Hogan D, et al. . Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. The Lancet 2015;385:430–40. 10.1016/S0140-6736(14)61698-6
- UNICEF One is too many. ending child deaths from pneumonia and diarrhea. New York: UNICEF, 2016.
- WHO Revised WHO classification and treatment of pneumonia in children at health facilities: evidence summaries. Geneva: World Health Organization, 2014.
- Hazir T, Nisar YB, Qazi SA, et al. . Chest radiography in children aged 2-59 months diagnosed with non-severe pneumonia as defined by World Health organization: descriptive multicentre study in Pakistan. BMJ 2006;333 10.1136/bmj.38915.673322.80
- Ginsburg AS, Mvalo T, Nkwopara E, et al. . Placebo vs amoxicillin for nonsevere Fast-Breathing pneumonia in Malawian children aged 2 to 59 months: a double-blind, randomized clinical Noninferiority trial. JAMA Pediatr 2018;3407.
- Gillies M, Ranakusuma A, Hoffmann T, et al. . Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication. CMAJ 2015;187:E21–31. 10.1503/cmaj.140848
- FDA Amoxil. Available: [Accessed 20 Dec 2018].
- Division of AIDS (DAIDS) Table for grading the severity of adult and pediatric adverse events, corrected version 2.1, 2017. Available: [Accessed 20 Dec 2018].
- Wiens MO, Pawluk S, Kissoon N, et al. . Pediatric post-discharge mortality in resource poor countries: a systematic review. PLoS One 2013;8:e66698 10.1371/journal.pone.0066698
Source: PubMed